Nasdaq · Healthcare

Revolution Medicines, Inc. (RVMD)

As-reported financials and recent SEC filings for Revolution Medicines, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

Net income

$-1.13B

Net margin

—

Diluted EPS

$-5.95

ROE

-69.3%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$0	$0	$11.6M	$35.4M	$29.4M
Gross profit	—	—	—	—	—
Operating income	$-1.18B	$-689.5M	$-487.2M	$-258.3M	$-188.0M
Net income	$-1.13B	$-600.1M	$-436.4M	$-248.7M	$-187.1M
Diluted EPS	$-5.95	$-3.58	$-3.86	$-3.08	$-2.57

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-01

1442026-06-29

42026-06-26

1442026-06-24

42026-06-23

42026-06-23

42026-06-23

42026-06-23

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on RVMD

Search Revolution Medicines, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.